NewAmsterdam Pharma Company NAMS FX Effect on Cash
FX Effect on Cash at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's fx effect on cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's FX effect on cash?
- NewAmsterdam Pharma Company (NAMS) reported FX effect on cash of -$1.33M in Q1 2026.
- How has NewAmsterdam Pharma Company's FX effect on cash changed year-over-year?
- NewAmsterdam Pharma Company's FX effect on cash decreased by 135.3% year-over-year, from $3.77M to -$1.33M.
- What is the long-term trend for NewAmsterdam Pharma Company's FX effect on cash?
- Over 3 years (2021 to 2025), NewAmsterdam Pharma Company's FX effect on cash has grown at a 39.9% compound annual growth rate (CAGR), from -$4.68M to $12.82M.
- What does FX effect on cash mean?
- The impact of exchange rate changes on the value of cash and equivalents held in foreign currencies.